摘要
并发慢性肾脏病(CKD)和心血管疾病(cardiovascular disease,CVD)是糖尿病患者死亡的主要原因,近几年来肾素-血管紧张素-醛固酮系统(renin-angiotensin-aldosterone system,RAAS)和利钠肽(natriuretic peptide,NP)系统的激活越发引起人们重视。能够同时拮抗脑啡肽酶和肾素-血管紧张素受体的药物被研制出来,其第一个代表药物是沙库巴曲缬沙坦,能够延缓患者心力衰竭和肾衰竭的进展,可作为糖尿病并发CKD和CVD患者的更优选择。本文基于以往研究阐述RAAS、NP系统与CKD和CVD的关系,并关于沙库巴曲缬沙坦对糖尿病并发CKD和CVD的保护作用进行综述。
Chronic kidney disease(CKD)and cardiovascular disease(CVD) are the major causes of death in patients with diabetes.The activation of renin-angiotensin-aldosterone system(RAAS) and natriuretic peptide(NP) system has attracted more and more attention in recent years.A dual-acting drug that simultaneously inhibits enkephalinase and renin-angiotensin has been developed.The first representative drug is Sacubitril Valsartan Sodium Tablet.It can delay the progression of heart failure and renal failure in patients,and can be a better choice for patients with diabetes complicated by CKD and CVD patients.Therefore,this study explores the relationship of RAAS and NP systems with CKD and CVD,and the protective effect of sacubitril valsartan on CKD and CVD with diabetes.
作者
杨慧娟
陈卫东
潘艳
YANG Hui-juan;CHEN Wei-dong;PAN Yan(Department of Nephrology,the First Affiliated Hospital of Bengbu Medical College,Bengbu 233000,China)
出处
《临床肾脏病杂志》
2020年第7期602-605,共4页
Journal Of Clinical Nephrology
